Volume 383, Issue 9928, Pages (May 2014)

Slides:

Advertisements

Similar presentations

Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4·4 million participants The Lancet Volume 387, Issue 10027,

Advertisements

Date of download: 6/22/2016 From: Systematic Review: Anti–Epidermal Growth Factor Receptor Treatment Effect Modification by KRAS Mutations in Advanced.

Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials The Lancet Volume 386, Issue.

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta- analysis of the randomised trials The Lancet Volume 386, Issue 10001,

Curative Treatment of Stage I Non-Small-Cell Lung Cancer in Patients With Severe COPD: Stereotactic Radiotherapy Outcomes and Systematic Review David.

Volume 16, Issue 2, Pages (February 2015)

Volume 386, Issue 9988, Pages (July 2015)

Volume 376, Issue 9747, Pages (October 2010)

Volume 383, Issue 9928, Pages (May 2014)

Volume 14, Issue 10, Pages (September 2013)

A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer Sarah Burdett, MSc,

Perioperative Blood Transfusion Is Associated With Worse Clinical Outcomes in Resected Lung Cancer Ting Wang, MD, Lili Luo, MD, He Huang, MD, Jingrui.

Lymphovascular Invasion as a Prognostic Indicator in Stage I Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis Nathan M. Mollberg, DO,

Masatsugu Hamaji, MD, Syed Osman Ali, MD, Bryan M. Burt, MD

Volume 5, Issue 4, Pages (April 2006)

Volume 384, Issue 9952, Pages (October 2014)

Volume 13, Issue 12, Pages (December 2012)

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Shidan Wang, BS, Lin Yang, MD, Bo Ci, BS, Matthew Maclean, BS, David E

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Volume 14, Issue 7, Pages (June 2013)

Perioperative Blood Transfusion Is Associated With Worse Clinical Outcomes in Resected Lung Cancer Ting Wang, MD, Lili Luo, MD, He Huang, MD, Jingrui.

Volume 375, Issue 9722, Pages (April 2010)

Adjuvant chemotherapy for rectal cancer – Authors' reply

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

Systematic review or meta-analysis

Volume 386, Issue 10001, Pages (October 2015)

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Lung cancer diagnosis and staging with endobronchial ultrasound-guided transbronchial needle aspiration compared with conventional approaches: an open-label,

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

Volume 13, Issue 12, Pages (December 2012)

Volume 386, Issue 10001, Pages (October 2015)

Survival Benefit of Neoadjuvant Chemotherapy in Non-small Cell Lung Cancer: An Updated Meta-Analysis of 13 Randomized Control Trials Wei-An Song, MD,

An Updated Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated.

Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline J Noble,

Volume 382, Issue 9890, Pages (August 2013)

Volume 18, Issue 3, Pages (March 2017)

A systematic review and meta-analysis of stereotactic body radiation therapy versus surgery for patients with non–small cell lung cancer Christopher.

Volume 393, Issue 10172, Pages (February 2019)

Volume 371, Issue 9627, Pages (May 2008)

Does Granulocyte Colony–Stimulating Factor Affect Survival in Patients with Advanced Non-small Cell Lung Cancer? Goulnar Kasymjanova, MD, Harvey Kreisman,

Volume 393, Issue 10172, Pages (February 2019)

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations Yelena Y.

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small.

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Volume 14, Issue 10, Pages (September 2013)

Volume 16, Issue 8, Pages (August 2015)

Volume 373, Issue 9658, Pages (January 2009)

Volume 373, Issue 9658, Pages (January 2009)

Volume 375, Issue 9719, Pages (March 2010)

Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient.

Performance Status and Smoking Status Are Independent Favorable Prognostic Factors for Survival in Non-small Cell Lung Cancer: A Comprehensive Analysis.

Volume 12, Issue 8, Pages (August 2013)

Preoperative versus Postoperative Chemotherapy in Patients with Resectable Non- small Cell Lung Cancer: Systematic Review and Indirect Comparison Meta-Analysis.

Volume 376, Issue 9747, Pages (October 2010)

Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28.

A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer Sarah Burdett, MSc,

Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis Sarah Burdett, Liselotte M. Boevé,

Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20 536 high-risk individuals: a randomised.

Probiotics for Prevention of Ventilator-Associated Pneumonia

Volume 388, Issue 10042, Pages (July 2016)

Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung.

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Postoperative chemotherapy for non–small cell lung cancer: A systematic review and meta-analysis Artyom Sedrakyan, MD, PhD, Jan van Der Meulen, PhD,

Node-Negative Non-small Cell Lung Cancer: Pathological Staging and Survival in 1765 Consecutive Cases Benjamin M. Robinson, BSc, MBBS, Catherine Kennedy,

Presentation transcript:

Volume 383, Issue 9928, Pages 1561-1571 (May 2014) Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data The Lancet Volume 383, Issue 9928, Pages 1561-1571 (May 2014) DOI: 10.1016/S0140-6736(13)62159-5 Copyright © 2014 NSCLC Meta-analysis Collaborative Group. Open Access article distributed under the terms of CC BY Terms and Conditions

Figure 1 Effect of preoperative chemotherapy on survival Each square denotes the HR for that trial comparison with the horizontal lines showing the 95% and 99% CIs. The size of the square is directly proportional to the amount of information contributed by the trial. The black diamond gives the pooled HR from the fixed effect model; the centre of this diamond denotes the HR and the extremities the 95% CI. O–E=observed minus expected. HR=hazard ratio. MIP=mitomycin, ifosphamide, cisplatin. SWOG=South West Oncology Group. JCOG=Japanese Cancer Oncology Group. MRC=Medical Research Council. BLT=Big Lung Trial. ChEST=Chemotherapy for Early Stages Trial. NATCH=Neoadjuvant/Adjuvant Trial of Chemotherapy. df=degrees of freedom. *Number of events/number entered. The Lancet 2014 383, 1561-1571DOI: (10.1016/S0140-6736(13)62159-5) Copyright © 2014 NSCLC Meta-analysis Collaborative Group. Open Access article distributed under the terms of CC BY Terms and Conditions

Figure 2 Kaplan-Meier curves (non-stratified) of the effect of preoperative chemotherapy on time to survival The Lancet 2014 383, 1561-1571DOI: (10.1016/S0140-6736(13)62159-5) Copyright © 2014 NSCLC Meta-analysis Collaborative Group. Open Access article distributed under the terms of CC BY Terms and Conditions

Figure 3 Forest plot of the interactions between the effect of preoperative chemotherapy on survival and covariates The circles represent (fixed effect) meta-analyses of the HRs representing the interactions between the effect of chemotherapy and patient characteristics; the horizontal line shows the 95% CI. HR=hazard ratio. The Lancet 2014 383, 1561-1571DOI: (10.1016/S0140-6736(13)62159-5) Copyright © 2014 NSCLC Meta-analysis Collaborative Group. Open Access article distributed under the terms of CC BY Terms and Conditions

Figure 4 Kaplan-Meier curves (non-stratified) of the effect of preoperative chemotherapy on time to distant and locoregional recurrence and recurrence-free survival Analyses of recurrence outcomes were calculated from a landmark time of 6 months from the date of randomisation; for this reason time on the x-axis starts at 6 months. The Lancet 2014 383, 1561-1571DOI: (10.1016/S0140-6736(13)62159-5) Copyright © 2014 NSCLC Meta-analysis Collaborative Group. Open Access article distributed under the terms of CC BY Terms and Conditions